AbstractCyclin-dependent kinase 9 (CDK9) is a promising target for cancer therapy due to its regulation of RNA polymerase II (RPB1) and key downstream anti-apoptosis proteins such as myeloid cell leukemia-1 (MCL-1). TP-1287 is a novel oral prodrug of alvocidib, a potent CDK9 inhibitor, and is currently under clinical investigation in patients with advanced solid tumors (clinicaltrials.gov, NCT03604783). TP-1287 is converted to alvocidib by alkaline phosphatases. CDK9 mediates phosphorylation of RPB1 at Ser2 and subsequently drives transcription of key oncogenic signaling genes, such as MCL-1. MCL-1 is a critical factor for survival of tumor types including acute myeloid leukemia (AML), multiple myeloma (MM) and myelodysplastic syndromes (MDS). MCL-1 is also expressed in normal peripheral blood mononuclear cells (PBMCs), thus it was hypothesized that CDK9 inhibition can be assessed clinically using PBMCs as a surrogate biomarker at multiple time points. We hypothesized that alvocidib, the pharmaceutically active form of TP-1287, would modulate CDK9 signaling pathways in cancer cells, resulting in tumor growth inhibition. In cell viability assays using CellTiter-Glo to evaluate the in vitro anti-tumor activity of alvocidib, we observed an IC50 of around 100 nM in AML and MM cell lines: 53-78 nM in MOLM-13, MV-4-11, and HL-60 AML cell lines and 31-223 nM in NCI-H929 and RPMI-8226 MM cell lines. In flow cytometry analysis, alvocidib reduced phosphorylation of RPB1 (p-RPB1) and MCL-1 protein expression in RPMI-8226 and MV-4-11 cells in a dose and time-dependent manner. In a pharmacodynamic study using the RPMI-8226 xenograft model after a single oral administration of TP-1287, we observed a substantial decrease of p-RPB1 and MCL-1 in tumor tissues followed by induction of cleaved caspase-3, an indicator of apoptosis. Furthermore, in an in vivo efficacy study using the RPMI-8226 model, TP-1287 achieved tumor growth inhibition (%TGI), ranging from 17.3% at 0.5 mg/kg (QD) to 86.6% at 15 mg/kg (Q7D) at day 22 after treatment. We hypothesized that PBMCs could serve as a surrogate tissue to measure CDK9 inhibition. To assess this approach in PBMCs, we performed ex vivo assays using human PBMCs from multiple healthy donors. Alvocidib demonstrated dose-dependent p-RPB1 and MCL-1 inhibition after 24 hr treatment. Preliminary data from the Phase 1 trial with TP-1287 showed p-RPB1 suppression in PBMCs from multiple patients, suggesting the successful execution of this assay and evidence of target engagement in the clinical setting. Taken together, TP-1287 demonstrated potent cell and tumor growth inhibition in multiple hematological cell lines, including AML and MM. Furthermore, a newly established flow cytometry system for p-RPB1 and MCL-1 to evaluate CDK9 inhibition in human PBMCs was developed, which could be useful as a surrogate biomarker for TP-1287 in clinical trials and warrants further investigation.Citation Format: Yuta Matsumura, Ethika Tyagi, Clifford J. Whatcott, Jason M. Foulks, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner. Pharmacodynamic biomarker strategies for CDK9 inhibition [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5813.

15 Aug 2020·Cancer Research

Abstract 1434: Loss of PTEN confers resistance to neddylation inhibition through TOP2A in glioblastoma

Author: Taylor, Brett ; Hartman, Lauren ; Dhruv, Harshil ; Lee, Matthew ; Berens, Michael ; Ferdosi, Shayesteh ; Reid, George ; Furnari, Frank ; Bybee, Rita ; Tang, Nanyun ; Vuori, Kristiina ; Finlay, Darren ; Peng, Sen

AbstractAs a disease that has not seen lasting advances in its standard of care for decades, glioblastoma (GBM) calls for novel therapeutic approaches, and given GBM's heterogeneous and aggressive nature, precision medicine stands out as an appealing treatment modality for this tragic disease. Neddylation is a post-translational modification process that regulates protein function and turnover. MLN4924, or Pevonedistat, inhibits the E1 ligase Nedd8 activating enzyme (NAE) and, in doing so, the E1, E2, and E3 neddylation cascade. In its most researched role, NEDD-8 is conjugated to the cullin subunit of cullin-RING ligases (CRLs), a family of E3 ligases that facilitate the ubiquitination of different substrates. Thus, inhibition of neddylation decreases ubiquitination and degradation of particular substrates: e.g., p21, p27, wee-1, and other cell cycle regulatory and pro-apoptotic proteins. We and others have shown that neddylation stands out a promising therapeutic approach to cancer and GBM, given the vulnerability to MLN4924 in subset of different in vitro and in vivo models. In this work, we establish the selective vulnerability to MLN4924 in GBM and explore the biological mechanisms that underlie this differential response. Using the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC) databases, we found that mutations and deletions in phosphatase and tensin homolog (PTEN) are associated with resistance to MLN4924 in both low-grade gliomas and GBM. Our established models validated these findings, as our sensitive models – GB1 (IC50= 0.28 μM) and LN18 (IC50 = 0.19 μM), – expressed PTEN, while our resistant models – M059K (IC50 = 5.5 μM) and SNU1105 (IC50 = 20.9 μM) – did not. Knocking down PTEN with siRNA in our sensitive models increased their IC50 values three- to four-fold. This relationship was further validated in multiple isogenic systems. We sought to uncover whether this PTEN-status dependent resistance was contingent on its well-studied lipid phosphatase activity and PI3K/AKT signaling. While the resistant models had higher baseline levels of phosphorylated AKT (p-AKT), we found that MLN4924 treatment did not consistently alter p-AKT levels in our sensitive and/or resistant models. We also used a PTEN null isogenic glioma stem cell system (GSC23), in which wild-type PTEN and lipid phosphatase dead (G129A) PTEN was re-expressed, and found that both PTEN models sensitized GSC23 to MLN4924 treatment equally. While independent of the PI3K/AKT axis, we did find that there were significant increases in topoisomerase II alpha (TOP2A) levels in the post-treatment lysate of our resistant (PTEN-null) models. Targeting this increase in TOP2A expression, we found strong synergy with two different TOP2 poisons – etoposide and doxorubicin – and MLN4924 in a combination DDR. For the first time, we show that PTEN status not only serves as a novel biomarker for MLN4924 response but also reveals a vulnerability to TOP2A inhibitors when used in combination with MLN4924.Citation Format: Brett Taylor, Shayesteh Ferdosi, Nanyun Tang, Rita Bybee, George Reid, Lauren Hartman, Darren Finlay, Kristiina Vuori, Matthew Lee, Sen Peng, Frank Furnari, Harshil Dhruv, Michael Berens. Loss of PTEN confers resistance to neddylation inhibition through TOP2A in glioblastoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1434.

01 Aug 2020·Molecular Cancer Research

Abstract B29: AXL Inhibitor TP-0903 attenuates TGFβ-Hippo signaling in lung adenocarcinoma cells

Author: Chen, Meizhen ; Chou, Chih-Wei ; Wade, Mark ; Nazarullah, Alia ; Lampkin, Shellye R. ; Taverna, Josephine A. ; Mouritsen, Lars ; Gaczynska, Maria E. ; Qiu, Lianquin ; Osmulski, Pawel A. ; Mesa, Ruben ; Bearss, David J. ; DeArmond, Daniel ; Wang, Chiou-Miin ; Huang, Tim H.-M. ; Lucio, Nicholas D. ; Lin, Chun-Lin ; Hung, Chia-Nung ; Kirma, Nameer ; Warner, Steve

AbstractBackground: Non-small cell lung cancer (NSCLC) is a molecularly heterogeneous disease with a high propensity for drug resistance and metastasis. AXL, a member of the Tyro3-AXL-Mer (TAM) family of receptor tyrosine kinases, is a central regulator of epithelial-to-mesenchymal transition (EMT) and enables tumor cells to invade and acquire drug resistance. AXL is overexpressed in NSCLC and its expression correlates positively with tumor invasion, drug resistance, and negatively predicts overall survival. We mechanistically interrogated the effects of the AXL inhibitor, TP-0903, on EMT in NSCLC cells using transcriptomic and proteomic profiling.Methods: Atomic force microscopy, Western blot analysis, RNA sequencing, and mass cytometry (CyTOF) were used to evaluate the phenotypic, transcriptomic, and proteomic profiles of A549 cells treated with 40 nM TP-0903 or shAXL knockdown. A549 and H1650 NSCLC xenograft models were used to explore the consequences of AXL inhibition in vivo.Results: As expected, TP-0903 treatment attenuated AXL signaling and downstream phosphorylation in the A549 cells. Interestingly, the treatment also reduced gene expression responses to TGFβ-Hippo signaling by disrupting the transcriptional complexes formed by SMAD2/3, SMAD4, YAP1, and TAZ. Consistent with AXL inhibition, TP-0903 reversed the mesenchymal phenotype in A549 and H2009 cell lines and decreased their migratory potential in culture. The CyTOF analysis on TP-0903-treated cells identified resistant clones overexpressing TGFβ receptor II (TGFBR2) and TAZ proteins and displaying hybrid EMT phenotypes. TP-0903 was also active in suppressing A549 or H1650 tumor growth in vivo.Conclusions: We are the first to report the interplay between AXL and TGFβ-Hippo signaling axis. TP-0903 has excellent therapeutic promise in NSCLC and we speculate that TP-0903 can target mesenchymal transitional states in NSCLC, possibly through the inhibition of the AXL-TGFβ-Hippo signaling axis.Citation Format: Josephine A. Taverna, Chia-Nung Hung, Chun-Lin Lin, Pawel A. Osmulski, Maria E. Gaczynska, Chiou-Miin Wang, Nicholas D. Lucio, Meizhen Chen, Chih-Wei Chou, Alia Nazarullah, Shellye R. Lampkin, Lianquin Qiu, David J. Bearss, Steve Warner, Lars Mouritsen, Mark Wade, Daniel DeArmond, Ruben Mesa, Nameer Kirma, Tim H.-M. Huang. AXL Inhibitor TP-0903 attenuates TGFβ-Hippo signaling in lung adenocarcinoma cells [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr B29.

News (Medical) associated with Tolero Pharmaceuticals, Inc.

13 Dec 2023

·www.biospace.com

Alternative Funding Strategies to Discuss at JPM

The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in 2024? Listen to this discussion on different kinds of funding options available, how companies can optimize their chances to secure funding and how they should be assessing VCs in addition to alternative partners – particularly if your company will be seeking funding at JPM this January. Our host and guests also discuss current challenges, how to weather adversity, and what investment trends are anticipated for next year. This roundtable discussion occurs Thursday, January 4. Subscribe below to receive an update with a link to the video the morning it goes live. By submitting your email address, you agree to receive communications from BioSpace. PANELISTS Jeff Burton | Halia Therapeutics | CFO Jeff Burton joined Halia Therapeutics as the Chief Financial Officer in December 2020. ‌Prior to coming to Halia, Jeff was with Tolero Pharmaceuticals where he helped guide the company through several rounds of funding, the acquisition of Tolero by Sumitomo Dainippon Pharma for $200 million upfront and $500 million in milestones, and provided support for the successful filing of five INDs and completion of nine clinical trials. ‌Prior to Tolero, Jeff was at Fusion-io, where he helped the company successfully complete its IPO, secondary offering, several acquisitions, key system implementations, and the eventual acquisition of Fusion-io by SanDisk for more than $1.1 billion. ‌Jeff holds Bachelor and Master of Accounting degrees from the University of Utah. Karen Harris | The Alzheimer’s Drug Discovery Foundation | CFO and Head of Mission-Related Investing Karen Harris is a member of the Alzheimer’s Drug Discovery Foundation’s executive team and serves as its Chief Financial Officer and Head of Mission Related Investments. ‌With a CFO background that spans both non-profits and investment banking, Ms. Harris is committed to increasing transparency and accessibility of complex financial information and heightening organizational effectiveness with robust financial governance, strategic planning, policies, controls, and training. She regularly presents to the ADDF’s Boards of Governors and Overseers, launched a board-level Finance and Audit Committee, and oversees the organization’s banking relationships. As Head of Mission Related Investments, Ms. Harris has also structured and stewarded dozens of venture-based investments for the ADDF, and she manages and monitors its extensive portfolio of securities and royalty arrangements with universities and biotech companies. ‌Previously, Ms. Harris served as Chief Financial Officer for the East Harlem Tutorial Program and Director of Development at Mount Sinai Adolescent Health Center. She also led a career in the financial sector for 20+ years prior to her transition to non-profit leadership. Among other roles, Ms. Harris served as Global COO for global equity capital markets, a $1 billion dollar division with 190 bankers at UBS, and as a Director and investment banker at Merrill Lynch. She earned an MBA in Finance from Stanford Graduate School of Business, graduating first in her class, and a BA in Economics from Columbia University. Rob Williamson | Triumvira Immunologics | President and COO Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. ‌Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a partner with The Boston Consulting Group and a research assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford. HOST ⁠⁠⁠⁠Lori Ellis⁠⁠⁠ | BioSpace | Head of Insights Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her current focus is on the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.⁠

Executive ChangeIPOAcquisition

20 Oct 2023

·www.fiercebiotech.com

Chutes & Ladders—Google DeepMind vet to join GSK as VP of artificial intelligence

None Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week. Google DeepMind vet to join GSK as VP of artificial intelligence GSK Bolstered by the recent ascension of Chat GPT and natural language models, incorporating artificial intelligence into drug development has been all the rage as of late. British pharma GSK is no exception and has made a critical hire to flesh out its efforts. The company has brought on Danielle Belgrave as vice president of artificial intelligence and machine learning. She was most recently at Google DeepMind, creating the health division with the deep learning unit. Her appointment was announced by Occam, the recruiting firm that helped bring her on. It’s actually Belgrave’s second stint with the company, having been a principal statistician with GSK for just less than a year in 2015. Now, less than 10 years later, she returns as an executive. In between, she spent four years as a research fellow in biomedical modeling at Imperial College London and a little more than three and a half years at Microsoft. Release Novartis radiopharma leader takes top job at Y-mAbs Y-mAbs Michael Rossi, who helped steer the U.S. business for Novartis’ radiopharma arm, has been named the new CEO of Y-mAbs Therapeutics. He’ll start Nov. 6. Rossi spent more than three years at Novartis from 2019 to 2022, first as a general manger for the U.S. business of Advanced Accelerator Applications, Novartis’ radiopharmaceutical division, before becoming head of radioligand imaging. He left in July 2022, becoming president of Mirion Medical a few months later in October. The unit’s work centers on developing imaging products and products that help improve radiation therapy. His new gig will take him from diagnostics and medical tools to actual drug development. Y-mAbs has been developing cancer-fighting antibodies, including FDA-approved Danyelza for patients with high-risk neuroblastoma. The biotech is also developing the drug as a treatment for relapsed second-line osteosarcoma. In addition to Rossi’s hiring, Y-mAbs co-founder, Thomas Gad, who’s been serving as interim CEO since last year, is being named chief business officer and VP of the board. His previous title, before adding on interim CEO duties, was president and head of business development and strategy. Release Genentech vet tapped to be CMO of Cargo Cargo Therapeutics Clinical-stage biotech Cargo Therapeutics is bringing on Genentech vet Ginna Laport, M.D., to be chief medical officer, a critical hire as the company proceeds with a potentially pivotal phase 2 trial for its lead asset. Laport was previously the vice president and head of global development for lymphoma and chronic lymphocytic leukemia at Genentech, a role she held for nearly four years. Prior to that, she was the chief medical officer of Tempest Therapeutics. Before jumping to industry, Laport spent 14 years on the faculty at Stanford University School of Medicine focused on hematology, oncology and bone marrow transplants. Cargo is working on a couple of cell therapies, namely CRG-022, which is in a phase 2 trial to treat patients with relapsed or refractory large B-cell lymphoma who previously tried a CD19-targeting cell therapy. Release > Flagship Pioneering’s Senda Biosciences and Laronde are merging into Sail Biomedicines. The new vessel will be helmed by Flagship CEO-Partner and Senda CEO Guillaume Pfefer, Ph.D., while Flagship Executive Partner John Mendlein, Ph.D., will serve as Sail’s executive chair. Fierce Biotech > Epic Bio has elected Weston Miller, M.D., to be the company’s chief medical officer, starting Oct. 23. Miller joins from Graphite Bio and has held roles at Astellas Gene Therapies and Sangamo Therapeutics. Release > Pliant Therapeutics has picked S. Mishima Gerhart as chief regulatory officer. She comes to Pliant from Taysha Gene Therapies and has previously held roles at Sanofi, Genzyme AbbVie, Reata Pharmaceuticals, Pfizer, AstraZeneca and Wyeth. Release > Genascence has grabbed Ian Lachlan (Lachy) McLean, M.D., Ph.D., to serve as chief medical officer. Before joining the gene therapy company, the rheumatologist was Novome’s CMO and has held roles of increasing seniority at AstraZeneca, Merck, Genentech, Takeda and Travere. Release > Summit Therapeutics has selected Manmeet Soni to be the company’s chief operating officer. Already a member of Summit’s board, Soni joins from Reata Pharmaceuticals up to its $7.5 billion acquisition by Biogen, where he was president, COO and chief financial officer. Release > Cartherics has chosen Walid Azar, Ph.D., to serve as chief scientific officer. Before joining the cancer biotech, he was a molecular biologist at CSL, where he was part of the international R&D team. Release > RegCell has tapped Michael McCullar, Ph.D., as its new president, CEO and representative director. McCullar previously served as the CEO of OnQuality Pharmaceuticals and has held leadership roles at Tolero Pharmaceuticals (acquired by Sumitomo Dainippon Pharma), Astex Pharmaceuticals (acquired by Otsuka Pharmaceuticals) and SuperGen. Release > Bob Lechleider, M.D., is joining Immunome as the company’s chief medical officer. Before Immunome, Lechleider was CMO at OncoResponse and SVP of clinical development for Seagen. Release > Catalyst Pharmaceuticals will be helmed by Richard Daly at the turn of the new year as founder, Chair and CEO Patrick McEnany retires Dec. 31. Daly most recently served as president of CARsgen Therapeutics Corporation and has held past leadership roles at Beyond Springs and Neuralstem. Release

Executive ChangePhase 2Drug ApprovalCell TherapyAcquisition

19 Oct 2023

·www.prnewswire.com

RegCell Appoints Experienced Life Science Executive and Entrepreneur Michael McCullar, Ph.D., MBA, as its New Chief Executive Officer

OSAKA, Japan, Oct. 19, 2023 /PRNewswire/ -- RegCell, a biotechnology company developing novel therapies for autoimmune diseases by leveraging the natural biology of regulatory T cells (Tregs) with its next-generation cell reprogramming platform, today announced the appointment of Michael V. McCullar, Ph.D., MBA as its new President, Chief Executive Officer, and Representative Director. "I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said Dr. Michael McCullar, Chief Executive Officer of RegCell. "In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities. I look forward to contributing my expertise towards validating the promising potential of our regulatory T cell platform and expanding our U.S. footprint as we advance our programs towards the clinic in 2024." Dr. McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades. Throughout his career, he has been involved in various aspects of drug development and played pivotal roles in the success of several pharmaceutical companies. Dr. McCullar formerly served as the CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities. Before that, he was Chief Operating Officer at Tolero Pharmaceuticals, where he had a prominent role in the company's acquisition by Sumitomo Dainippon Pharma and has also served as the Senior Vice President of Business Development at Astex Pharmaceuticals, which was eventually acquired by Otsuka Pharmaceuticals. Dr. McCullar has held several high-level executive positions at SuperGen, showcasing his commitment and upward career path within the company. His journey at SuperGen culminated in the role of Senior Vice President of Strategy and Operations, where his expertise paved the way for the U.S. Food and Drug Administration (FDA) approval of Dacogen as a treatment for myelodysplastic syndromes. RegCell was co-founded by Prof. Shimon Sakaguchi, a distinguished Professor at Osaka University and Kyoto University, who is world-renowned for his discovery of Tregs in 1995. The company has developed a proprietary regulatory T cell platform that has demonstrated strong preclinical validation as a potential transformational therapeutic product to restore immune tolerance in autoimmune disorders, which are typically characterized by the depletion or the presence of dysfunctional Tregs. Prof. Shimon Sakaguchi, Founder and Technical Advisor of RegCell added, "Dr. McCullar's extensive experience in leading all phases of research and development, as well as his collaborative leadership style, will be an invaluable addition to RegCell as the company advances towards the first in human validation trials. Our S/F-Epigen-Treg technology for autologous cell therapy has the potential to target a large number of autoimmune diseases without suppressing the overall immune system, and we are confident that Dr. McCullar's leadership will ensure we reach the ultimate goal of reversing autoimmune disorders in patients." About RegCell RegCell is a preclinical-stage biotechnology company located in Japan with investment from leading Japanese institutional investors, including The University of Tokyo Edge Capital Partners. RegCell has developed a best-in-class proprietary platform that allows the generation of epigenetically reprogrammed antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-Epigen-Tregs) to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation. For more information visit: Media Contact: Ignacio Guerrero-Ros, Ph.D. Russo Partners LLC [email protected] SOURCE RegCell

Executive ChangeCell TherapyAcquisitionImmunotherapy

100 Deals associated with Tolero Pharmaceuticals, Inc.

100 Translational Medicine associated with Tolero Pharmaceuticals, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dubermatinib ( AXL )	Neuroblastoma More	Pending
SGI-7079 ( AXL )	Neoplasms More	Pending
TP-4207 ( BTK )	Chronic Lymphocytic Leukemia More	Pending
TP-0413 ( BMPs x Hepc )	Anemia More	Pending
MKC-4659 ( BTK )	Hematologic Neoplasms More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis